Researchers reviewed the effects of direct-acting antiviral therapies on the extrahepatic manifestations of HCV.
Researchers aimed to characterize serological, virological, and histological profiles during and after multidose ARC-520 treatment in patients with chronic HBV.
Investigators conducted an international, multicenter meta-analysis to assess HCC recurrence risk in patients treated with DAAs.
Researchers launched a simplified model of HCV care through decentralized health services within rural Cambodia.
The researchers’ objective was to determine the prevalence of HCV antibodies among MSM with and without HIV, as well as factors associated with HCV infection among MSM.
All five patients were hospitalized but have since recovered.
A team of investigators examined differences in outcomes according to sex in risk for acute coronary syndrome, end-stage renal disease, and ischemic stroke by treatment and response in a large US-based multisite cohort of patients with hepatitis C virus infection.
While DAAs have improved the treatment of chronic HCV infection by eliciting higher rates of sustained virologic response, they also interact with a number of agents that could potentially limit their effectiveness.
Eight weeks of treatment with glecaprevir/pibrentasvir is both efficacious and well tolerated in treatment-naive patients with HCV.
Researchers evaluated the prevalence of serologic immunity against hepatitis B virus in immunocompromised patients with pediatric-onset inflammatory bowel disease and rheumatologic diseases.
ASCO recommends that patients with newly diagnosed cancer slated to receive systemic anticancer meds be tested for HBV by 3 tests prior to starting therapy.
New CDC guidelines recommend a test-and-treat approach for healthcare personnel who may have been exposed to acute hepatitis C virus infection at work.
Recommendations are presented for testing and clinical management of health care personnel exposed to the hepatitis C virus in a US Centers for Disease Control and Prevention guidance report.
Routine hepatitis C virus testing at federally qualified health centers would be cost-effective and could improve outcomes for people with HCV infections.
By providing bundled HIV and HCV testing, substance use disorder treatment programs may create increased awareness of infection status among people with substance abuse disorders.
Researchers found that no patients with concomitant COVID-19 and hepatitis B virus infection progressed to severe or critically ill status during hospitalization, but many had abnormal liver function tests on admission.
TDF therapy resulted in greater rates of elastographic reversion of cirrhosis in patients with chronic hepatitis B at year 5 compared with entecavir.
A combined hepatitis A and typhus vaccine in Australia for use in patients aged > 16 years was shown to be well-tolerated in children aged 2 to 16 years.
Study data supports the long-term efficacy and safety of besifovir dipivoxil maleate (BSV) for the treatment of chronic hepatitis B (CHB).
Patients using statins had a lower risk for any acute liver injury outcome within 18 months compared with non-users, regardless of HIV and/or hepatitis C virus (HCV) status.